pharmaceutical companies

Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers struggling to fund late-stage drug development and global expansion. What Happened: According to UBS Research, companies like Merck (NYSE:MRK), GSK (NYSE:GSK), and AstraZeneca (...

IGC Pharma Inc (AMEX:IGC) recently entered into a Master Cooperation Agreement with the University of Los Andes, focusing on integrating generative AI solutions into various aspects of drug development and clinical trials.  This collaboration aims to enhance the efficiency of clinical trials,...

AstraZeneca plc (NYSE: AZN) second-quarter earnings beat estimates as demand for its therapies centered on diabetes and cancer remained strong, with the drugmaker also working on a potential coronavirus vaccine. What Happened The British drugmaker recorded sales of $6.28 billion and...

Analysts at Argus no longer hold a bullish view on Mylan N.V. (NASDAQ: MYL) after the company cut its full-year guidance and cautioned that its earnings per share will decline in 2017. The firm's Jasper Hellweg downgraded Mylan's stock rating from Buy to Hold as the stock is fairly valued at its...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) gained more than 3.5 percent early Thursday morning after the company announced the sale of one of its business units. Valeant has agreed to sell its iNova Pharmaceuticals business for $930 million to a group advised and managed by major...

Elemer Piros of Cantor Fitzgerald maintains an Overweight rating on Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)'s stock with a $14 price target after the company reported data from a Phase 2b study, which helped boost the stock higher by more than 5 percent. During the National Kidney Foundation...

Imprimis Pharmaceuticals Inc (NASDAQ: IMMY), a nano-cap pharmaceutical company that owns, markets and dispenses a portfolio of compounded therapeutic in several areas, reported improved quarterly results on a year-over-year basis. The company reported a loss of $0.44 per share in the fourth quarter...

Merck & Co., Inc. (NYSE: MRK)'s KEYTRUDA is a therapy used to combat a form of skin cancer called melanoma. It can also be used to treat a kind of lung cancer called non-small cell lung cancer. The U.S. Food and Drug Administration announced on Nov. 28, 2016, it has granted a Priority Review...

Mallinckrodt PLC (NYSE: MNK), a developer of branded and generic specialty pharmaceutical products and therapies, is a popular stock among short sellers. Back in January, Martin Shkreli explained to Benzinga why a Federal Trade Commission lawsuit against the company is justified. Prior to that,...

Recro Pharma Inc (NASDAQ: REPH) is a clinical-stage pharmaceutical company that engages in the development of products for the treatment of serious acute pain. The company's lead product candidate is called meloxicam, which is an IV intravenous product for relief of serious pain that is...

Gary Nachman of BMO Capital Markets has some good news and bad news for Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s investors following the company's third-quarter earnings report. The good news is that Valeant's new segment reporting could provide greater visibility on its business outlook. The...

Brenton Saunders is the CEO and president of Allergan plc Ordinary Shares (NYSE: AGN), and on Tuesday, he clarified what he believes to be the core components of an already existing "social contract" with stakeholders. In a blog post, Saunders stated he understands the recent public outcry against...

Shares of Celgene Corporation (NASDAQ: CELG) were trading higher by 0.43 percent at $108.11 after the company reported its second-quarter results. Celgene said it earned $1.44 per share in the second quarter on revenue of $2.74 billion. Wall Street analysts were expecting the company to earn $1.39...

After gaining a sufficient understanding of the importance of clinical Phase I and Phase II trials, it's time to move on to the importance of Phase III trials. To recap, a Phase I trial consists of a pharmaceutical company testing a new drug or treatment in a small group of people to evaluate its...